(EMAILWIRE.COM, August 10, 2018 ) An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.

Over the next five years, projects that Orally Disintegrating Tablet will register a 11.3% CAGR in terms of revenue, reach US$ 21300 million by 2023, from US$ 11200 million in 2017.

Get Sample Copy of this Report @ https://www.researchbeam.com/2018-2023-global-orally-disintegrating-tablet-consumption-report-market/request-sample

The classification of Orally Disintegrating Tablet includes Anti-Psychotics Drug, Anti-Epileptics Drug and others, and the proportion of Anti-Psychotics Drug in 2017 is about 16.6%, Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20.3% revenue share of the global market by 2025 end. With a noteworthy 15.7% CAGR, this segment will retain its supremacy over other drug class segments during the eight-year period.

Under by Disease Indication, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases and Others. CNS Diseases segment will hold maximum revenue share in the global market, and the consumption proportion is about 53.4% in 2017. and forecasts indicate a 57.2% market share for this segment by the end of the forecast period in 2025.

North America is the largest consumption place, with a consumption market share nearly 40.5% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 31.6%, China is also an important sales region for the Orally Disintegrating Tablet.

This report presents a comprehensive overview, market shares, and growth opportunities of Orally Disintegrating Tablet market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segmentation by application:

CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
Get a discount on this research report: https://www.researchbeam.com/2018-2023-global-orally-disintegrating-tablet-consumption-report-market/purchase-enquiry

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Conquer

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Orally Disintegrating Tablet consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Orally Disintegrating Tablet market by identifying its various subsegments.
Focuses on the key global Orally Disintegrating Tablet manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Orally Disintegrating Tablet with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Orally Disintegrating Tablet submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Read More: https://www.researchbeam.com/2018-2023-global-orally-disintegrating-tablet-consumption-report-market

About Us:

Research Beam is a high end and wide online market for market research reports that contain detailed and rational market research. Research Beam is a one stop report destination that offers clients well drafted and accurately analyzed report with insightful data.

We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities. Research Beam will always make sure to bring most ethical and high quality reports. We value your relationship with us and look forward for a long term relation.

Contact Us

Global Head Quarters

5933 NE Win Sivers Drive,

#205, Portland, OR 97220

United States

+1 (800) 910-6452

help@researchbeam.com

Contact Information:
Research Beam
Research Beam
Tel: +1 (800) 910-6452
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results